Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis

References

• American Psychiatric Association. 2022. Position statement on the use of psychedelic and empathogenic agents for mental health conditions [Internet]. American Psychiatric Association. Accessed June 4, 2023. https://www.psychiatry.org/getattachment/d5c13619-ca1f-491f-a7a8-b7141c800904/Position-Use-of-Psychedelic-Empathogenic-Agents.pdf
   Google Scholar
• Andersen, K. A. A., R. Carhart-Harris, D. J. Nutt, and D. Erritzoe. 2021. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica February 143(2):101–18. doi: 10.1111/acps.13249.
   PubMed Web of Science ®Google Scholar
• Bahji, A., A. Forsyth, D. Groll, and E. R. Hawken. 2020. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry January 10 96:109735. doi:10.1016/j.pnpbp.2019.109735.
   PubMed Web of Science ®Google Scholar
• Bahji, A., G. H. Vazquez, and C. A. Zarate. 2021. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders January 1 278: 542–55. doi:10.1016/j.jad.2020.09.071.
   PubMed Web of Science ®Google Scholar
• Bahji, A., C. A. Zarate, and G. H. Vazquez. 2021. Ketamine for bipolar depression: A systematic review. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) July 23 24 (7):535–41. doi:10.1093/ijnp/pyab023.
   PubMed Web of Science ®Google Scholar
• Bahji, A., C. A. Zarate, and G. H. Vazquez. 2022. Efficacy and safety of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Expert Opinion on Drug Safety June 21(6):853–66. doi: 10.1080/14740338.2022.2047928.
   PubMed Web of Science ®Google Scholar
• Balduzzi, S., G. Rücker, and G. Schwarzer. 2019. How to perform a meta-analysis with R: A practical tutorial. Evidence-Based Mental Health November 1 22 (4):153–60. doi:10.1136/ebmental-2019-300117.
   PubMed Web of Science ®Google Scholar
• Berkovitch, L., B. Roméo, L. Karila, R. Gaillard, and A. Benyamina. 2021. Efficacy of psychedelics in psychiatry, a systematic review of the literature. L’Encephale August 1 47 (4):376–87. doi:10.1016/j.encep.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Bouso, J. C., R. Doblin, M. Farré, A. MÁ, and G. Gómez-Jarabo. 2008. MDMA-Assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs Septemeber 1 40 (3):225–36. doi:10.1080/02791072.2008.10400637.
   PubMed Web of Science ®Google Scholar
• Breeksema, J. J., B. W. Kuin, J. Kamphuis, W. van den Brink, E. Vermetten, and R. A. Schoevers. 2022. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Journal of Psychopharmacology (Oxford, England) October 36(10):1100–17. doi: 10.1177/02698811221116926.
   PubMed Web of Science ®Google Scholar
• Breeksema, J. J., A. R. Niemeijer, E. Krediet, E. Vermetten, and R. A. Schoevers. 2020. Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs September 1 34 (9):925–46. doi:10.1007/s40263-020-00748-y.
   PubMed Web of Science ®Google Scholar
• Button, K. S., and M. R. Munafö. 2015. Addressing risk of bias in trials of cognitive behavioral therapy. Shanghai Arch Psychiatry June 25 27 (3):144–48. doi:10.11919/j.issn.1002-0829.215042.
   PubMedGoogle Scholar
• Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, D. J. Nutt et al. 2021. Trial of Psilocybin versus Escitalopram for Depression. The New England Journal of Medicine. 384(15):1402–11. doi:10.1056/NEJMoa2032994.
   PubMed Web of Science ®Google Scholar
• Chen, H., P. Cohen, and S. Chen. 2010. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Communications in Statistics - Simulation and Computation March 31 39 (4):860–64. doi:10.1080/03610911003650383.
   Web of Science ®Google Scholar
• Ching, T. H., M. T. Williams, J. B. Wang, L. Jerome, B. Yazar-Klosinski, A. Emerson, and R. Doblin. 2022. MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two phase 2 open-label lead-in trials and a phase 3 randomized, blinded placebo-controlled trial. Journal of Psychopharmacology August 1 36 (8):974–86. doi:10.1177/02698811221104052.
   PubMed Web of Science ®Google Scholar
• Cohen, J. 1988. Statistical power analysis for the behavioral sciences. Hillsdale, N.J: L. Erlbaum Associates.
   Google Scholar
• Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021 May 1;78(5):481–89.
   PubMed Web of Science ®Google Scholar
• dos Santos RG, J. C. Bouso, M. Á. Alcázar-Córcoles, A.-C. MÁ, and R. G. dos Santos. 2018. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Review of Clinical Pharmacology September 2 11 (9):889–902. doi:10.1080/17512433.2018.1511424.
   PubMed Web of Science ®Google Scholar
• dos Santos RG, F. L. Osório, J. A. S. Crippa, J. Riba, A. W. Zuardi, J. E. C. Hallak, and R. G. dos Santos. 2016. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): A systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology June 1 6 (3):193–213. doi:10.1177/2045125316638008.
   PubMed Web of Science ®Google Scholar
• Duval, S., and R. Tweedie. 2000. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics June 56(2):455–63. doi: 10.1111/j.0006-341X.2000.00455.x.
   PubMed Web of Science ®Google Scholar
• Egger, M., G. Davey Smith, M. Schneider, and C. Minder. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ September 13 315 (7109):629–34. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Eisenstein, M. 2022. The psychedelic escape from depression. Nature September 28 609 (7929):S87–9. doi:10.1038/d41586-022-02872-9.
   PubMedGoogle Scholar
• Friedrich, M. J. 2017. Depression is the leading cause of disability around the world. JAMA April 18 317 (15):1517–1517. doi:10.1001/jama.2017.3826.
   Web of Science ®Google Scholar
• Fuentes, J. J., F. Fonseca, M. Elices, M. Farré, and M. Torrens. 2020. Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials. Frontiers in Psychiatry / Frontiers Research Foundation [Internet] January 21 Accessed February 28, 2021 10. doi:10.3389/fpsyt.2019.00943
   Google Scholar
• Furukawa, T. A., C. Barbui, A. Cipriani, P. Brambilla, and N. Watanabe. 2006. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology January 1 59 (1):7–10. doi:10.1016/j.jclinepi.2005.06.006.
   PubMed Web of Science ®Google Scholar
• Furukawa, T. A., A. Cipriani, C. Barbui, P. Brambilla, and N. Watanabe. 2005. Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology January 20(1):49–52. doi: 10.1097/00004850-200501000-00010.
   PubMed Web of Science ®Google Scholar
• Galvão-Coelho, N. L., W. Marx, M. Gonzalez, J. Sinclair, M. de Manincor, D. Perkins, et al. 2021. Classic serotonergic psychedelics for mood and depressive symptoms: A meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) February 1 238 (2):341–54. doi:10.1007/s00213-020-05719-1.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., B. Kersgaard, and P. H. Addy. 2016. Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology August 24(4):229–68. doi: 10.1037/pha0000084.
   PubMed Web of Science ®Google Scholar
• Gasser, P., D. Holstein, Y. Michel, R. Doblin, B. Yazar-Klosinski, T. Passie, et al. 2014. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. Journal of Nervous & Mental Disease July 202 (7):513–20. doi:10.1097/NMD.0000000000000113.
   PubMed Web of Science ®Google Scholar
• Goodwin, G. M., S. T. Aaronson, O. Alvarez, P. C. Arden, A. Baker, J. C. Bennett, C. Bird, R. E. Blom, C. Brennan, D. Brusch, et al. 2022. Single-dose psilocybin for a treatment-resistant episode of Major depression. The New England Journal of Medicine November 3 387 (18):1637–48. doi:10.1056/NEJMoa2206443.
   PubMed Web of Science ®Google Scholar
• Goodwin, G. M., S. T. Aaronson, O. Alvarez, M. Atli, J. C. Bennett, M. Croal, C. DeBattista, B. W. Dunlop, D. Feifel, D. J. Hellerstein, et al. 2023. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders April 327:120–27. doi:10.1016/j.jad.2023.01.108.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology December 30(12):1181–97. doi: 10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Grob, C. S., A. L. Danforth, G. S. Chopra, M. Hagerty, C. R. McKay, A. L. Halberstadt, et al. 2011. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry January 68 (1):71–78. doi:10.1001/archgenpsychiatry.2010.116.
   PubMed Web of Science ®Google Scholar
• Gukasyan, N., A. K. Davis, F. S. Barrett, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, and R. R. Griffiths. 2022. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology 36 (2):151–58. doi:10.1177/02698811211073759.
   PubMed Web of Science ®Google Scholar
• Guyatt, G. H., A. D. Oxman, G. E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, et al. 2008. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ April 24 336 (7650):924–26. doi:10.1136/bmj.39489.470347.AD.
   PubMed Web of Science ®Google Scholar
• Hedges, L. V. 1981. Distribution theory for glass’s estimator of effect size and related estimators. Journal of Educational Statistics 6 (2):107–28. doi:10.3102/10769986006002107.
   Google Scholar
• Holze, F., P. Gasser, F. Müller, P. C. Dolder, and M. E. Liechti. 2023. Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study. Biological Psychiatry February 93(3):215–23. doi: 10.1016/j.biopsych.2022.08.025.
   PubMed Web of Science ®Google Scholar
• Katzman, M. A., P. Bleau, P. Blier, P. Chokka, K. Kjernisted, and M. Van Ameringen. 2014. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry July 2 14 (1):S1. doi:10.1186/1471-244X-14-S1-S1.
   PubMed Web of Science ®Google Scholar
• Kennedy, S. H., R. W. Lam, R. S. McIntyre, S. V. Tourjman, V. Bhat, P. Blier, M. Hasnain, F. Jollant, A. J. Levitt, G. M. MacQueen, et al. 2016. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. The Canadian Journal of Psychiatry September 61 (9):540–60. doi:10.1177/0706743716659417.
   PubMed Web of Science ®Google Scholar
• Kisely, S., M. Connor, A. A. Somogyi, and D. Siskind. 2023. A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. The Australian and New Zealand Journal of Psychiatry March 57(3):362–78. doi: 10.1177/00048674221083868.
   PubMed Web of Science ®Google Scholar
• Ladova, K., J. Vlcek, M. Vytrisalova, and J. Maly. 2014. Healthy adherer effect - the pitfall in the interpretation of the effect of medication adherence on health outcomes. Journal of Evaluation in Clinical Practice April 20(2):111–16. doi: 10.1111/jep.12095.
   PubMed Web of Science ®Google Scholar
• Ledwos, N., J. D. Rosenblat, D. M. Blumberger, D. J. Castle, R. S. McIntyre, B. H. Mulsant, et al. 2022. A critical appraisal of evidence on the efficacy and safety of serotonergic psychedelic drugs as emerging antidepressants: Mind the evidence Gap. Journal of Clinical Psychopharmacology December 1 42 (6):581–88. doi:10.1097/JCP.0000000000001608.
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A. 2021. Back to the future — the therapeutic potential of psychedelic drugs. The New England Journal of Medicine April 15 384 (15):1460–61. doi:10.1056/NEJMe2102835.
   PubMed Web of Science ®Google Scholar
• Mastinu, A., M. Anyanwu, M. Carone, G. Abate, S. A. Bonini, G. Peron, E. Tirelli, M. Pucci, G. Ribaudo, E. Oselladore, et al. 2023. The bright side of psychedelics: Latest advances and challenges in neuropharmacology. International Journal of Molecular Sciences 24 (2):1329. doi:10.3390/ijms24021329.
   PubMed Web of Science ®Google Scholar
• McIntyre, R. S., M. J. Filteau, L. Martin, S. Patry, A. Carvalho, D. S. Cha, et al. 2014. Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders March 156:1–7. doi:10.1016/j.jad.2013.10.043.
   PubMed Web of Science ®Google Scholar
• M, O. G., J. Grigsby, B. Poulter, J. W. Van Derveer, S. G. Giron, L. Jerome, A. A. Feduccia, S. Hamilton, B. Yazar-Klosinski, A. Emerson, et al. 2018. 3,4-methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. Journal of Psychopharmacology December 32 (12):1295–307. doi:10.1177/0269881118806297.
   PubMed Web of Science ®Google Scholar
• Milev, R. V., P. Giacobbe, S. H. Kennedy, D. M. Blumberger, Z. J. Daskalakis, J. Downar, M. Modirrousta, S. Patry, F. Vila-Rodriguez, R. W. Lam, et al. 2016. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 4. The Canadian Journal of Psychiatry September 61 (9):561–75. doi:10.1177/0706743716660033.
   PubMed Web of Science ®Google Scholar
• Mitchell, J. M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, et al. 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine May 10:1–9.
   PubMedGoogle Scholar
• Mithoefer, M. C., A. A. Feduccia, L. Jerome, A. Mithoefer, M. Wagner, Z. Walsh, S. Hamilton, B. Yazar-Klosinski, A. Emerson, R. Doblin, et al. 2019. MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl) September 1 236 (9):2735–45. doi:10.1007/s00213-019-05249-5.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., A. T. Mithoefer, A. A. Feduccia, L. Jerome, M. Wagner, J. Wymer, J. Holland, S. Hamilton, B. Yazar-Klosinski, A. Emerson, et al. 2018. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry June 1 5 (6):486–97. doi:10.1016/S2215-0366(18)30135-4.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., M. T. Wagner, A. T. Mithoefer, L. Jerome, and R. Doblin. 2011. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology April 25(4):439–52. doi: 10.1177/0269881110378371.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., M. T. Wagner, A. T. Mithoefer, L. Jerome, S. F. Martin, B. Yazar-Klosinski, Y. Michel, T. D. Brewerton, and R. Doblin. 2013. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology January 27(1):28–39. doi: 10.1177/0269881112456611.
   PubMed Web of Science ®Google Scholar
• Montgomery, S. A., and M. Asberg. 1979. A new depression scale designed to be sensitive to change. British Journal of Psychiatry April 134(4):382–89. doi: 10.1192/bjp.134.4.382.
   PubMed Web of Science ®Google Scholar
• Munder, T., H. Gerger, S. Trelle, and J. Barth. 2011. Testing the allegiance bias hypothesis: A meta-analysis. Psychotherapy Research Journal Society Psychotherapy Research November 21(6):670–84. doi: 10.1080/10503307.2011.602752.
   PubMed Web of Science ®Google Scholar
• Murphy, R., H. Kettner, R. Zeifman, B. Giribaldi, L. Kartner, J. Martell, T. Read, A. Murphy-Beiner, M. Baker-Jones, D. Nutt, et al. 2022. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Frontiers in Pharmacology 12:788155. doi:10.3389/fphar.2021.788155.
   PubMed Web of Science ®Google Scholar
• Muthukumaraswamy, S. D., A. Forsyth, and T. Lumley. 2021. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology September 14(9):1133–52. doi: 10.1080/17512433.2021.1933434.
   PubMed Web of Science ®Google Scholar
• Muthukumaraswamy, S., A. Forsyth, and R. L. Sumner. 2022. The challenges ahead for psychedelic “medicine. The Australian and New Zealand Journal of Psychiatry March 4:48674221081763.
   Google Scholar
• Muttoni, S., M. Ardissino, and C. John. 2019. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders November 1 258: 11–24. doi:10.1016/j.jad.2019.07.076.
   PubMed Web of Science ®Google Scholar
• Nutt, D., and R. Carhart-Harris. 2021. The Current status of psychedelics in psychiatry. JAMA Psychiatry February 1 78 (2):121–22. doi:10.1001/jamapsychiatry.2020.2171.
   PubMed Web of Science ®Google Scholar
• Oehen, P., R. Traber, V. Widmer, and U. Schnyder. 2013. A randomized, controlled pilot study of MDMA (± 3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). Journal of Psychopharmacology (Oxford, England) January 27(1):40–52. doi: 10.1177/0269881112464827.
   PubMed Web of Science ®Google Scholar
• Page, M. J., J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, et al. 2021. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ March 29 372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes, F., D. Barreto, H. Onias, K. C. Andrade, M. M. Novaes, J. A. Pessoa, S. A. Mota-Rolim, F. L. Osório, R. Sanches, R. G. dos Santos, et al. 2019. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine March 49 (4):655–63. doi:10.1017/S0033291718001356.
   PubMed Web of Science ®Google Scholar
• Phelps, J., R. N. Shah, and J. A. Lieberman. 2022. The rapid rise in investment in psychedelics—cart before the horse. JAMA Psychiatry March 1 79 (3):189–90. doi:10.1001/jamapsychiatry.2021.3972.
   PubMed Web of Science ®Google Scholar
• Reiche, S., L. Hermle, S. Gutwinski, H. Jungaberle, P. Gasser, and T. Majić. 2018. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Progress in Neuro-Psychopharmacology & Biological Psychiatry February 2 81: 1–10. doi:10.1016/j.pnpbp.2017.09.012.
   PubMed Web of Science ®Google Scholar
• Rosenblat, J. D., M. I. Husain, Y. Lee, R. S. McIntyre, R. B. Mansur, D. Castle, H. Offman, S. V. Parikh, B. N. Frey, A. Schaffer, et al. 2022. The Canadian network for mood and anxiety treatments (CANMAT) task force report: Serotonergic psychedelic treatments for major depressive disorder. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie August 68:5–21. doi:10.1177/07067437221111371.
   PubMed Web of Science ®Google Scholar
• Rosenblat, J. D., M. I. Husain, Y. Lee, R. S. McIntyre, R. B. Mansur, D. Castle, H. Offman, S. V. Parikh, B. N. Frey, A. Schaffer, et al. 2023. The Canadian network for mood and anxiety treatments (CANMAT) task force report: Serotonergic psychedelic treatments for major depressive disorder. The Canadian Journal of Psychiatry January 68 (1):5–21. doi:10.1177/07067437221111371.
   PubMed Web of Science ®Google Scholar
• Ross, S. 2018. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry July 4 30 (4):317–30. doi:10.1080/09540261.2018.1482261.
   PubMed Web of Science ®Google Scholar
• Ross, S., A. Bossis, J. Guss, G. Agin-Liebes, T. Malone, B. Cohen, S. E. Mennenga, A. Belser, K. Kalliontzi, J. Babb, et al. 2016. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology December 30 (12):1165–80. doi:10.1177/0269881116675512.
   PubMed Web of Science ®Google Scholar
• RSdio Team. RStudio: Integrated development environment for R [Internet]. Boston, MA: The R Foundation for Statistical Computing; 2022. (RStudio). http://www.rstudio.com/.
   Google Scholar
• Rucker, J. J. H., J. Iliff, and D. J. Nutt. 2018. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology November 1 142: 200–18. doi:10.1016/j.neuropharm.2017.12.040.
   PubMed Web of Science ®Google Scholar
• Rucker, J. J., L. A. Jelen, S. Flynn, K. D. Frowde, and A. H. Young. 2016. Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology (Oxford, England) December 30(12):1220–29. doi: 10.1177/0269881116679368.
   PubMed Web of Science ®Google Scholar
• Samara, M. T., L. M. Spineli, T. A. Furukawa, R. R. Engel, J. M. Davis, G. Salanti, and S. Leucht. 2013. Imputation of response rates from means and standard deviations in schizophrenia. Schizophrenia Research December 1 151 (1):209–14. doi:10.1016/j.schres.2013.10.029.
   PubMed Web of Science ®Google Scholar
• Sarri, G., E. Patorno, H. Yuan, J. Guo, D. Bennett, X. Wen, A. R. Zullo, J. Largent, M. Panaccio, M. Gokhale, et al. 2022. Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making. BMJ Evidence-Based Medicine April 1 27 (2):109–19. doi:10.1136/bmjebm-2020-111493.
   PubMedGoogle Scholar
• Schatzberg, A. F. 2020. Some comments on psychedelic research. The American Journal of Psychiatry May 177(5):368–69. doi: 10.1176/appi.ajp.2020.20030272.
   PubMed Web of Science ®Google Scholar
• Shi, L., and L. Lin. 2019. The trim-and-fill method for publication bias: Practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore) June 7 98 (23):e15987. doi:10.1097/MD.0000000000015987.
   PubMed Web of Science ®Google Scholar
• Sloshower, J., P. D. Skosnik, H. Safi-Aghdam, S. Pathania, S. Syed, B. Pittman, and D. C. D’Souza. 2023. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal of Psychopharmacology March 37:698–706. doi: 10.1177/02698811231154852.
   PubMed Web of Science ®Google Scholar
• Solmi, M., C. Chen, C. Daure, A. Buot, M. Ljuslin, V. Verroust, L. Mallet, Y. Khazaal, S. Rothen, G. Thorens, et al. 2022. A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology November 1 64:44–60. doi:10.1016/j.euroneuro.2022.09.004.
   PubMed Web of Science ®Google Scholar
• Sterne, J. A. C., J. Savović, M. J. Page, R. G. Elbers, N. S. Blencowe, I. Boutron, C. J. Cates, H.-Y. Cheng, M. S. Corbett, S. M. Eldridge, et al. 2019. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ August 28 366:l4898. doi:10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Sterne, J. A. C., A. J. Sutton, J. P. A. Ioannidis, N. Terrin, D. R. Jones, J. Lau, J. Carpenter, G. Rucker, R. M. Harbord, C. H. Schmid, et al. 2011. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ July 22 343:d4002. doi:10.1136/bmj.d4002.
   PubMed Web of Science ®Google Scholar
• Sterne, J. A. C., I. R. White, J. B. Carlin, M. Spratt, P. Royston, M. G. Kenward, et al. 2009. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ September 1 338 (jun 29 1):b2393–b2393. doi:10.1136/bmj.b2393.
   PubMedGoogle Scholar
• Vargas, M. V., R. Meyer, A. A. Avanes, M. Rus, and D. E. Olson. 2021. Psychedelics and other psychoplastogens for treating mental illness. Frontiers in Psychiatry / Frontiers Research Foundation [Internet] Accessed September 24, 2022 12. doi: 10.3389/fpsyt.2021.727117
   Google Scholar
• Veritas Health Innovation. 2019. Covidence systematic review software. Melbourne, Australia.
   Google Scholar
• Von Rotz, R., E. M. Schindowski, J. Jungwirth, A. Schuldt, N. M. Rieser, K. Zahoranszky, E. Seifritz, A. Nowak, P. Nowak, L. Jäncke, et al. 2023. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine February 56:101809. doi:10.1016/j.eclinm.2022.101809.
   PubMedGoogle Scholar
• Wolfson, P. E., J. Andries, A. A. Feduccia, L. Jerome, J. B. Wang, E. Williams, S. C. Carlin, E. Sola, S. Hamilton, B. Yazar-Klosinski, et al. 2020. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Scientific Reports November 24 10 (1):20442. doi:10.1038/s41598-020-75706-1.
   PubMed Web of Science ®Google Scholar
• Yaden, D. B., M. E. Yaden, and R. R. Griffiths. 2021. Psychedelics in psychiatry—keeping the renaissance from going off the rails. JAMA Psychiatry May 1 78 (5):469–70. doi:10.1001/jamapsychiatry.2020.3672.
   PubMed Web of Science ®Google Scholar